Innoviva
INVAINVA · Stock Price
Historical price data
Overview
Innoviva operates a distinctive hybrid business model, leveraging long-term royalty streams from partnered respiratory drugs like TRELEGY and ANORO to fund strategic R&D and acquisitions. The company has successfully transitioned from its origins as Theravance into a financially robust entity with a $1.69B market cap, using its cash generation to build a promising pipeline in oncology and anti-infectives. Its strategy focuses on disciplined capital allocation, targeting late-stage or commercial assets to drive future growth while maintaining a strong balance sheet.
Technology Platform
A hybrid 'innotecture' model combining royalty monetization expertise with strategic acquisition and development of late-stage clinical assets, supplemented by a proprietary bacteriophage therapy platform for antibiotic-resistant infections.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Angiotensin-II | Vasodilatory Shock | Approved | |
| Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Cef... | Mycobacterium Abscessus Pulmonary Disease | Phase 2 | |
| Eravacycline 2mg/kg + Eravacycline 1.5mg/kg | Complicated Intra-abdominal Infections (cIAI) | Phase 2 | |
| Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sul... | Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) | Phase 1 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In respiratory, it competes indirectly via its partner GSK against giants like AstraZeneca. In anti-infectives, it faces specialized biotechs in both the antibiotic and emerging phage therapy spaces, but its financial strength from royalties provides a distinct capital advantage.
